Transatlantique Private Wealth LLC Sells 1,060 Shares of Illumina, Inc. (NASDAQ:ILMN)

Transatlantique Private Wealth LLC lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 35.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,925 shares of the life sciences company’s stock after selling 1,060 shares during the quarter. Transatlantique Private Wealth LLC’s holdings in Illumina were worth $202,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Trivant Custom Portfolio Group LLC lifted its holdings in Illumina by 166.7% during the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 125 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in Illumina by 86.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after buying an additional 132 shares during the period. Industrial Alliance Investment Management Inc. acquired a new stake in Illumina during the 2nd quarter worth approximately $34,000. Versant Capital Management Inc boosted its holdings in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the period. Finally, Principal Securities Inc. bought a new stake in shares of Illumina during the fourth quarter worth $51,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ILMN shares. Barclays raised shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 target price for the company in a research note on Wednesday, August 14th. Evercore ISI decreased their price objective on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. Royal Bank of Canada restated an “outperform” rating and issued a $242.00 target price on shares of Illumina in a research note on Wednesday, August 14th. Scotiabank decreased their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research note on Thursday, August 15th. Finally, Robert W. Baird lifted their price objective on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $151.05.

Illumina Stock Down 2.4 %

Shares of ILMN opened at $131.20 on Friday. The firm has a market cap of $20.90 billion, a P/E ratio of -16.10 and a beta of 1.15. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $148.19. The firm’s 50-day simple moving average is $125.25 and its 200 day simple moving average is $120.57.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.24. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm’s quarterly revenue was down 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 EPS. On average, analysts forecast that Illumina, Inc. will post 3.62 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.